-
1
-
-
0035922444
-
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
-
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
-
(2001)
N Engl J Med
, vol.345
, pp. 870-878
-
-
Parving, H.H.1
Lehnert, H.2
Brochner-Mortensen, J.3
Gomis, R.4
Andersen, S.5
Arner, P.6
-
2
-
-
0035922441
-
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
-
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
-
(2001)
N Engl J Med
, vol.345
, pp. 861-869
-
-
Brenner, B.M.1
Cooper, M.E.2
de Zeeuw, D.3
-
3
-
-
0037031270
-
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect
-
MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators
-
Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
-
(2002)
Circulation
, vol.106
, pp. 672-678
-
-
Viberti, G.1
Wheeldon, N.M.2
-
4
-
-
0141789624
-
Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis
-
Jafar TH, Stark PC, Schmid CH, et al: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-253.
-
(2003)
Ann Intern Med
, vol.139
, pp. 244-253
-
-
Jafar, T.H.1
Stark, P.C.2
Schmid, C.H.3
-
5
-
-
0038460302
-
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report
-
Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
-
(2003)
JAMA
, vol.289
, pp. 2560-2572
-
-
Chobanian, A.V.1
Bakris, G.L.2
Black, H.R.3
-
6
-
-
34548383480
-
ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
-
Mancia G, De Backer G, Dominiczak A, et al: 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-1762.
-
(2007)
J Hypertens
, vol.2007
, Issue.25
, pp. 1751-1762
-
-
Mancia, G.1
De Backer, G.2
Dominiczak, A.3
-
7
-
-
34249905442
-
Reduction of microalbuminuria in patients with type 2 diabetes: The Shiga Microalbuminuria Reduction Trial (SMART)
-
Shiga Microalbuminuria Reduction Trial (SMART) Group
-
Shiga Microalbuminuria Reduction Trial (SMART) Group: Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care 2007; 30: 1581-1583.
-
(2007)
Diabetes Care
, vol.30
, pp. 1581-1583
-
-
-
8
-
-
0037431774
-
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial
-
Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124.
-
(2003)
Lancet
, vol.361
, pp. 117-124
-
-
Nakao, N.1
Yoshimura, A.2
Morita, H.3
Takada, M.4
Kayano, T.5
Ideura, T.6
-
9
-
-
0038185261
-
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER
-
Mogensen CE, Viberti G, Halimi S, et al: Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063-1071.
-
(2003)
Hypertension
, vol.41
, pp. 1063-1071
-
-
Mogensen, C.E.1
Viberti, G.2
Halimi, S.3
-
10
-
-
0037213037
-
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
-
Adler AI, Stevens RJ, Manley SE, et al: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
-
(2003)
Kidney Int
, vol.63
, pp. 225-232
-
-
Adler, A.I.1
Stevens, R.J.2
Manley, S.E.3
-
11
-
-
1042302788
-
Nephropathy in diabetes
-
American Diabetes Association
-
American Diabetes Association: Nephropathy in diabetes. Diabetes Care 2004; 27(Suppl 1): S79-S83.
-
(2004)
Diabetes Care
, vol.27
, Issue.SUPPL. 1
-
-
-
12
-
-
0034700790
-
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
-
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators
-
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
-
(2000)
Lancet
, vol.355
, pp. 253-259
-
-
-
13
-
-
0035948631
-
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
-
Gerstein HC, Mann JF, Yi Q, et al: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc 2001; 286: 421-426.
-
(2001)
J Am Med Assoc
, vol.286
, pp. 421-426
-
-
Gerstein, H.C.1
Mann, J.F.2
Yi, Q.3
-
14
-
-
0035989568
-
Microalbuminuria: Marker of vascular dysfunction, risk factor for cardiovascular disease
-
Garg JP, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002; 7: 35-43.
-
(2002)
Vasc Med
, vol.7
, pp. 35-43
-
-
Garg, J.P.1
Bakris, G.L.2
-
15
-
-
34249746896
-
Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes
-
Araki S, Haneda M, Koya D, et al: Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007; 56: 1727-1730.
-
(2007)
Diabetes
, vol.56
, pp. 1727-1730
-
-
Araki, S.1
Haneda, M.2
Koya, D.3
-
16
-
-
34248178511
-
Albiminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
-
Eijkelkamp WB, Zhang Z, Resmuzzi G, et al: Albiminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1540-1546
-
-
Eijkelkamp, W.B.1
Zhang, Z.2
Resmuzzi, G.3
-
17
-
-
0036833657
-
Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: A randomized double-blind placebo-conrolled crossover study
-
Sasso FC, Carbonara O, Persico M, et al: Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-conrolled crossover study. Diabetes Care 2002; 25: 1909-1913.
-
(2002)
Diabetes Care
, vol.25
, pp. 1909-1913
-
-
Sasso, F.C.1
Carbonara, O.2
Persico, M.3
-
18
-
-
0042804810
-
Effect of losartan on micro-albuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial
-
Zandbergen AA, Baggen Lamberg SW, Bootsma AH, de Zeeuw D, Ouwendijk RJ: Effect of losartan on micro-albuminuria in normotensive patients with type 2 diabetes mellitus. A randomized clinical trial. Ann Intern Med 2003; 139: 90-96.
-
(2003)
Ann Intern Med
, vol.139
, pp. 90-96
-
-
Zandbergen, A.A.1
Baggen Lamberg, S.W.2
Bootsma, A.H.3
de Zeeuw, D.4
Ouwendijk, R.J.5
-
20
-
-
0035964911
-
Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels
-
Haasen PB, Jensen BL, Andreansen D, Skott O: Differential expression of T- and L-type voltage-dependent calcium channels in renal resistance vessels. Circ Res 2001; 89: 630-638.
-
(2001)
Circ Res
, vol.89
, pp. 630-638
-
-
Haasen, P.B.1
Jensen, B.L.2
Andreansen, D.3
Skott, O.4
-
21
-
-
33745683627
-
Comparison between valsartan and valsartan plus calsidipine in type II diabetics with normo- microalbuminoria
-
Katayama K, Nomura S, Ishikawa H, et al: Comparison between valsartan and valsartan plus calsidipine in type II diabetics with normo- microalbuminoria. Kidney Int 2006; 70: 151-156.
-
(2006)
Kidney Int
, vol.70
, pp. 151-156
-
-
Katayama, K.1
Nomura, S.2
Ishikawa, H.3
-
22
-
-
36749047471
-
Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive with chronic renal disease
-
Fujita T, Ando K, Nishimura H, et al: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive with chronic renal disease. Kidney Int 2007; 72: 1543-1549.
-
(2007)
Kidney Int
, vol.72
, pp. 1543-1549
-
-
Fujita, T.1
Ando, K.2
Nishimura, H.3
-
23
-
-
34548028268
-
Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis
-
Ishimitsu T, Kameda T, Akashiba A, et al: Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-626.
-
(2007)
Hypertens Res
, vol.30
, pp. 621-626
-
-
Ishimitsu, T.1
Kameda, T.2
Akashiba, A.3
-
24
-
-
34249897487
-
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losactan in chronic renal insufficiency
-
Hou FF, Xie D, Zhang X, et al: Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losactan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18: 1889-1898.
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1889-1898
-
-
Hou, F.F.1
Xie, D.2
Zhang, X.3
|